News
BACK
0.055
NaN%
--
Weekly Report: what happened at BACK last week (0330-0403)?
Weekly Report · 1d ago
IMAC Holdings files to deregister common stock, suspending SEC reporting duty
Reuters · 6d ago
Weekly Report: what happened at BACK last week (0323-0327)?
Weekly Report · 03/30 09:48
Weekly Report: what happened at BACK last week (0316-0320)?
Weekly Report · 03/23 09:45
IMAC Holdings Announces Private Placement of Equity Securities
TipRanks · 03/19 20:37
IMAC Holdings announces unregistered sale of 36 million USD in convertible preferred stock
Reuters · 03/19 20:01
Weekly Report: what happened at BACK last week (0309-0313)?
Weekly Report · 03/16 09:45
Weekly Report: what happened at BACK last week (0302-0306)?
Weekly Report · 03/09 09:46
Weekly Report: what happened at BACK last week (0223-0227)?
Weekly Report · 03/02 09:46
IMAC Holdings Secures New Short-Term Liquidity Financing
TipRanks · 02/27 21:49
Weekly Report: what happened at BACK last week (0216-0220)?
Weekly Report · 02/23 09:45
Imac Holdings Secures New Short-Term Promissory Note Financing
TipRanks · 02/18 13:49
Weekly Report: what happened at BACK last week (0209-0213)?
Weekly Report · 02/16 09:45
Weekly Report: what happened at BACK last week (0202-0206)?
Weekly Report · 02/09 09:46
Weekly Report: what happened at BACK last week (0126-0130)?
Weekly Report · 02/02 09:45
Imac Holdings Secures Short-Term Promissory Note Financing
TipRanks · 01/30 22:01
IMAC Holdings Secures $222,600 Promissory Note Financing
Reuters · 01/30 21:37
Weekly Report: what happened at BACK last week (0119-0123)?
Weekly Report · 01/26 09:46
Weekly Report: what happened at BACK last week (0112-0116)?
Weekly Report · 01/19 09:50
IMAC Holdings enters short-term secured financing agreement
TipRanks · 01/16 21:39
More
Webull provides a variety of real-time BACK stock news. You can receive the latest news about Imac Hldgs Inc through multiple platforms. This information may help you make smarter investment decisions.
About BACK
IMAC Holdings, Inc. provides services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company, through its subsidiary, Ignite Proteomics LLC (Ignite Proteomics), leverages its multi-analyte proteomic assay to help oncologists pinpoint the effective targeted therapies for each patient. Its product is a patented Reverse Phase Protein Array (RPPA) technology platform, which can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. Ignite Proteomics operates a CLIA-certified and CAP-accredited laboratory and offers single-gene tests by evaluating entire protein pathways in cancer cells. Its commercially available lab developed test (LDT), the Ignite RPPA Assay for Breast Cancer, is being utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.